Search

Your search keyword '"Van Den Berg, Leonard H"' showing total 1,385 results

Search Constraints

Start Over You searched for: Author "Van Den Berg, Leonard H" Remove constraint Author: "Van Den Berg, Leonard H" Search Limiters Available in Library Collection Remove constraint Search Limiters: Available in Library Collection
1,385 results on '"Van Den Berg, Leonard H"'

Search Results

1. Molecular pathology, developmental changes and synaptic dysfunction in (pre-) symptomatic human C9ORF72-ALS/FTD cerebral organoids

3. ATAXIN-2 intermediate-length polyglutamine expansions elicit ALS-associated metabolic and immune phenotypes

5. Functional characterisation of the amyotrophic lateral sclerosis risk locus GPX3/TNIP1

6. Mechanism-free repurposing of drugs for C9orf72-related ALS/FTD using large-scale genomic data

8. A randomized double-blind clinical trial on safety and efficacy of tauroursodeoxycholic acid (TUDCA) as add-on treatment in patients affected by amyotrophic lateral sclerosis (ALS): the statistical analysis plan of TUDCA-ALS trial

10. Genome-wide association study of intracranial aneurysms identifies 17 risk loci and genetic overlap with clinical risk factors

11. Addressing heterogeneity in amyotrophic lateral sclerosis CLINICAL TRIALS.

12. The contribution of Neanderthal introgression and natural selection to neurodegenerative diseases

14. Revised Airlie House consensus guidelines for design and implementation of ALS clinical trials

15. Genome-wide identification of the genetic basis of amyotrophic lateral sclerosis

16. 10Kin1day: A Bottom-Up Neuroimaging Initiative

18. Structural variation analysis of 6,500 whole genome sequences in amyotrophic lateral sclerosis

19. Lithium carbonate in amyotrophic lateral sclerosis patients homozygous for the C-allele at SNP rs12608932 in UNC13A: protocol for a confirmatory, randomized, group-sequential, event-driven, double-blind, placebo-controlled trial

20. DNA Methylation Analysis Identifies Loci for Blood Pressure Regulation

21. Genetic correlation between amyotrophic lateral sclerosis and schizophrenia.

22. Pathogenic Huntingtin Repeat Expansions in Patients with Frontotemporal Dementia and Amyotrophic Lateral Sclerosis

23. European Academy of Neurology (EAN) guideline on the management of amyotrophic lateral sclerosis in collaboration with European Reference Network for Neuromuscular Diseases (ERNEURO‐NMD)

25. Safety and efficacy of arimoclomol in patients with early amyotrophic lateral sclerosis (ORARIALS-01): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial

26. Assessment of risk of ALS conferred by the GGGGCC hexanucleotide repeat expansion in C9orf72 among first-degree relatives of patients with ALS carrying the repeat expansion

27. Mutations in the tail and rod domains of the neurofilament heavy-chain gene increase the risk of ALS

28. A comparison between bioelectrical impedance analysis and air-displacement plethysmography in assessing fat-free mass in patients with motor neurone diseases: a cross-sectional study

29. Trial Participation in Neurodegenerative Diseases: Barriers and Facilitators: A Systematic Review and Meta-Analysis

32. Association Between Hypothalamic Volume and Metabolism, Cognition, and Behavior in Patients With Amyotrophic Lateral Sclerosis

33. A 21-bp deletion in the complement regulator CD55 promotor region is associated with multifocal motor neuropathy and its disease course

34. Mutations in the tail and rod domains of the neurofilament heavy-chain gene increase the risk of ALS

35. European Academy of Neurology (EAN) guideline on the management of amyotrophic lateral sclerosis in collaboration with European Reference Network for Neuromuscular Diseases (ERN EURO-NMD)

36. Safety, tolerability, and pharmacokinetics of antisense oligonucleotide BIIB078 in adults with C9orf72-associated amyotrophic lateral sclerosis: a phase 1, randomised, double blinded, placebo-controlled, multiple ascending dose study

37. Remote monitoring of amyotrophic lateral sclerosis using wearable sensors detects differences in disease progression and survival: a prospective cohort study

38. Revisiting distinct nerve excitability patterns in patients with amyotrophic lateral sclerosis

39. The ALSFRS-R Summit: a global call to action on the use of the ALSFRS-R in ALS clinical trials

40. European academy of neurology (EAN) guideline on the management of amyotrophic lateral sclerosis in collaboration with European reference network for neuromuscular diseases (ERN EURO-NMD)

41. ALS-associated C21ORF2 variant disrupts DNA damage repair, mitochondrial metabolism, neuronal excitability and NEK1 levels in human motor neurons

42. ATAXIN-2 intermediate-length polyglutamine expansions elicit ALS-associated metabolic and immune phenotypes

43. Molecular pathology, developmental changes and synaptic dysfunction in (pre-) symptomatic human C9ORF72-ALS/FTD cerebral organoids

45. Familial motor neuron disease: co-occurrence of PLS and ALS (-FTD)

46. IgM anti-GM2 antibodies in patients with multifocal motor neuropathy target Schwann cells and are associated with early onset

47. Validating biomarkers and models for epigenetic inference of alcohol consumption from blood

48. Common Genetic Variants Contribute to Risk of Transposition of the Great Arteries

49. Anti-C2 Antibody ARGX-117 Inhibits Complement in a Disease Model for Multifocal Motor Neuropathy

50. No evidence for shared genetic basis of common variants in multiple sclerosis and amyotrophic lateral sclerosis

Catalog

Books, media, physical & digital resources